A chromatin remodeling checkpoint of diet-induced macrophage activation in adipose tissue

ARTICLE INFO

Keywords
Adipose tissue
BAF60a
Diabetes
Inflammation
Macrophage
Obesity

ABSTRACT

The interplay between the environment and the immune cells is linked to metabolic homeostasis under physiologic and pathophysiologic conditions. Diabetes mellitus type 2 (T2D) is considered an immune-related inflammatory disorder, in which the adipose tissue macrophages (ATMs) are key players orchestrating metabolic chronic meta-inflammation and contributing to the pathogenesis of metabolic disease. However, the molecular regulators that integrate the environmental signals to control ATM activation and adipose inflammation during obesity and T2D remain unclear. Epigenetic mechanisms constitute important parameters in metabolic homeostasis, obesity and T2D via the integration of the environmental factors to the transcriptional regulation of gene programs. In a very recent study published in Diabetes by Kong et al., BAF60a has been identified as a key chromatin remodeling checkpoint factor that associates obesity-associated stress signals with meta-inflammation and systemic homeostasis. Furthermore, this work uncovers Atf3 as an important downstream effector in BAF60a-mediated chromatin remodeling and transcriptional reprogramming of macrophage activation in adipose tissue. The findings of this research may contribute to the development of new therapeutic approaches for obesity-induced metabolic inflammation and associated metabolic disorders.

Adipose tissue has been recently recognized as an active endocrine organ producing several cytokines and biopeptides termed adipokines, which play a critical and dynamic role in fine-tuning metabolism and body homeostasis [1–4]. Obesity represents a chronic subclinical inflammation which is characterized by the increased expression of pro-inflammatory cytokines, adipokines and chemokines, such as Tumor Necrosis Factor-α (TNF-α), interleukin (IL)-1β, IL-6, leptin, resistin, visfatin, chemokine (C–C motif) ligand 5 (Ccl5), and Ccl2, whereby the interplay between adipose tissue macrophages (ATMs) and the micro-environment in adipose tissue plays a crucial role [4–11]. Obesity-associated metabolic dysfunction of the adipose tissue is a significant factor in the pathogenesis of insulin resistance and Type 2 diabetes (T2D). ATMs are dynamically implicated in modulating metabolic homeostasis and the immune milieu in the adipose tissue [9–13]. The interplay between the environment and the immune cells is connected with metabolic homeostasis under pathophysiologic conditions. T2D is considered an immune-related inflammatory disease, in which the ATMs are key players orchestrating metabolic chronic meta-inflammation and contributing to the pathogenesis of metabolic disease [11–13]. M1 polarization (classical activation characterized by the production of pro-inflammatory cytokines and chemokines such as IL-6, IL-12 and TNF-α which may impair insulin action in adipocytes) and M2 polarization (alternative activation characterized by the secretion of anti-inflammatory cytokines protecting adipocytes from inflammation and damage) of ATM present an equilibrium in physiologic conditions. In contrast, during obesity, macrophages that are recruited in the adipose tissue acquire a pro-inflammatory phenotype. Interestingly, there is a distinct metabolically activated phenotype of ATMs, which is different from the M1/M2 activation [11–13]. However, the molecular regulators that integrate the environmental signals to control ATM activation and adipose inflammation during obesity and T2D remain unclear.

A previous study has demonstrated that epigenetic mechanisms are essential for metabolic homeostasis since they serve important roles in the pathogenesis of obesity and diabetes through integrating the environmental factors to the transcriptional regulation of gene programs [11]. In recent years, switch/sucrose-nonfermentable (SWI/SNF) chromatin-remodeling complexes composed of multiple subunits have been shown to play a crucial role in diverse pathophysiologic processes. The BAF60 family members, including BAF60a, BAF60b and BAF60c, can recruit the SWI/SNF complex to target genes to remodel nucleosomes structure and transcription [12]. Recently, a research article published in Diabetes titled “BAF60a Deficiency in Macrophage Promotes Diet-Induced Obesity and Metabolic Inflammation” by Kong et al. has identified BAF60a as a pivotal chromatin remodeling checkpoint factor to regulate macrophage pro-inflammatory activation in white adipose tissue upon high fat diet (HFD) feeding [13]. Moreover, the authors also unveiled that BAF60a/Atf3 axis is the key regulator in obesity-associated ATM activation, adipose tissue inflammation and metabolic dysfunction.

It has been previously reported that BAF60a is enriched in liver and adipose tissue, and is mainly involved in regulating fatty acid oxidation, cholesterol homeostasis, circadian regulation of hepatic energy metabolism, and adipose tissue thermogenesis [14–17]. BAF60c is highly expressed in skeletal muscle, especially in white muscle with more glycolysis, and plays a key role in glucose sensing, utilization, and regulation of glucose homeostasis [18–21]. BAF60b is highly expressed

https://doi.org/10.1016/j.metopen.2022.100204
Received 23 July 2022; Accepted 23 July 2022
Available online 31 July 2022
2589-9368/© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in immune cells with an identity of the important regulator in mediating granulocyte development [22]. However, the role of BAF60 proteins in obesity-induced macrophage activation and chronic inflammation in adipose tissue remains unclear.

In this new study [13], the authors first observed that expression of BAF60a, but not BAF60b and BAF60c, is significantly reduced in stromal vascular fraction (SVF) of white adipose tissue (WAT) in diabetic mice compared to those from control mice. Further studies have shown that the lower expression of BAF60a in SVFs is mainly due to the down-regulation of BAF60a expression in macrophages in response to palmitic acid; PA: Palmitic acid; TNF-α: Tumor Necrosis factor-α.

Addition, this work uncovers Atf3 as an important downstream effector of BAF60a-mediated chromatin remodeling and transcriptional reprogramming of macrophage activation in adipose tissue. The findings of this research may contribute to the development of new therapeutic approaches for obesity-induced metabolic inflammation and associated metabolic disorders.

Conflict of interest
None.

Funding information
None.

References
[1] Dalamaga M, Christodoulousta GS, Karampela I, Vallianou N, Aparisional CM. Understanding the Co-epidemic of obesity and COVID-19: current evidence, comparison with previous epidemics, mechanisms, and preventive and therapeutic perspectives. Curr Obes Rep 2021;10:214–43. https://doi.org/10.1007/s13679-021-00436-y.
[2] Kassi E, Dalamaga M, Hroussalas G, Kazanis K, Merantzi G, Zachari A, Giamarellos-Bourboulis EJ, Dionysios-Asteriou A. Adipocyte factors, high-sensitive C-reactive protein levels and lipolysaccharide stress products in overweight and postmenopausal women with normal and impaired OGTT. Maturitas 2010;67:72–7. https://doi.org/10.1016/j.maturitas.2010.05.004.
[3] Dalamaga M, Papadavids E, Bastos G, Vaggopoulos V, Rigopoulos D, Kastania AN, Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study. J Am Acad Dermatol 2013;69:922–30. https://doi.org/10.1016/j.jaad.2013.09.014.
[4] Kassi E, Dalamaga M, Faviou E, Hroussalas G, Kazanis K, Kountelia G, Dionysios-Asteriou A. Circulating oxidized LDL levels, current smoking and obesity in postmenopausal women. Atherosclerosis 2009;205:279–83. https://doi.org/10.1016/j.atherosclerosis.2009.07.026.
[5] Papadavids E, Gazi S, Dalamaga M, Stavrianeas N, Theodorou V, Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol 2008;22:380–2. https://doi.org/10.1111/j.1468-2339.2007.02235.x.
[6] Dalamaga M, Karmaniolos K, Arsenis G, Pantelaki M, Dalamaga M, M. Papadavids E, M. Migdalis I, Cedeceaa lapagei bacteremia following cement-related chemical burn injury. Burns 2008;34:1205–7. https://doi.org/10.1016/j.burns.2007.09.001.
[7] Dalamaga M, Karampela I, Mantzoros CS. Commentary: phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism 2020;109:154282. https://doi.org/10.1016/j.metabol.2020.
[8] Marouga A, Dalamaga M, Kastania AN, Koupric C, Lagoj M, Sasoates K, Dimas K, Vlahakos DV. Circulating resistin is a significant predictor of mortality independently from cardiovascular comorbidities in elderly, non-diabetic subjects with chronic kidney disease. Biomarkers 2016;21:73–9. https://doi.org/10.3109/13547539.2015.1118536.
[9] Hroussalas G, Kassi E, Dalamaga M, Delimaris I, Zachari A, Dionysios-Asteriou A. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women. Maturitas 2008;59:339–49. https://doi.org/10.1016/j.maturitas.2008.03.012.
[10] Marouga A, Dalamaga M, Kastania AN, Antakonakis G, Tharysouloudas A, Kontelis G, Dimas K, Vlahakos DV. Correlates of serum resistin in elderly, non-diabetic patients with chronic kidney disease. Clin Lab 2013;59:1121–8. https://doi.org/10.1016/j.clinlab.2012.121112.
[11] Ling C, Ronn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab 2019;29:1028–44. https://doi.org/10.1016/j.cmet.2019.03.009.
[12] Wang RR, Pan R, Zhang W, Fu J, Lin JD, Meng ZX. The SWI/SNF chromatin-remodeling factors BAF60a, b, and c in nutrient signaling and metabolic control. Protein Cell 2019;10:207–15. https://doi.org/10.1007/s13238-017-0442-2.
[13] Kong Q, Zou J, Zhang Z, Pan R, Zhang YZ, Han S, Xu Y, Gao Y, Meng ZX. BAF60a deficiency in macrophage promotes diet-induced obesity and metabolic inflammation. Diabetes 2022. https://doi.org/10.2337/db22-0114.
[14] Meng ZX, Wang L, Chang L, Sun J, Bao J, Li Y, Chen YE, Lin JD. A diet-sensitive BAF60a-mediated pathway links hepatic bile acid metabolism to cholesterol absorption and atherosclerosis. Cell Rep 2015;13:1658–69. https://doi.org/10.1016/j.celrep.2015.10.032.
[15] Liu T, Mi L, Xiong J, Orchard P, Yu Q, Yu L, Zhao XY, Meng ZX, Parker SJ, Lin JD, Li S. BAF60a deficiency uncouples chromatin accessibility and cold sensitivity from white fat browning. Nat Commun 2020;11:2379. https://doi.org/10.1038/s41467-020-16148-1.
[16] Tao W, Chen S, Shi G, Guo J, Xu Y, Liu C. SWItch/sucrose nonfermentable (SWI/SNF) complex subunit BAF60a integrates hepatic circadian clock and energy metabolism. Hepatology 2011;54:1410–20. https://doi.org/10.1002/hep.24514.

[17] Zhang W, Dong Z, Xu M, Zhang S, Liu C, Chen S. SWI/SNF complex subunit BAF60a represses hepatic ureagenesis through a crosstalk between YB-1 and PGC-1α. Mol Metab 2020;32:85–96. https://doi.org/10.1016/j.molmet.2019.12.007.

[18] Meng ZX, Gong J, Chen Z, Sun J, Xiao Y, Wang I, Li Y, Liu J, Xu XZS, Lin JD. Glucose sensing by skeletal myocytes couples nutrient signaling to systemic homeostasis. Mol Cell 2017;66:332–44. https://doi.org/10.1016/j.molcel.2017.04.007. e334.

[19] Meng ZX, Li S, Wang I, Ko HJ, Lee Y, Jung DY, Okutsu M, Yan Z, Kim JK, Lin JD. Baf60c drives glycolytic metabolism in the muscle and improves systemic glucose homeostasis through Deptor-mediated Akt activation. Nat Med 2013;19:640–5. https://doi.org/10.1038/nm.3144.

[20] Meng ZX, Tao W, Sun J, Wang Q, Mi L, Lin JD. Uncoupling exercise bioenergetics from systemic metabolic homeostasis by conditional inactivation of Baf60 in skeletal muscle. Diabetes 2018;67:85–97. https://doi.org/10.2337/db17-0367.

[21] Michel BC, Kadoch C. A SMARCD2-containing mSWI/SNF complex is required for granulopoiesis. Nat Genet 2017;49:655–7. https://doi.org/10.1038/ng.3853.